Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data

Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data

Immunic (IMUX) has announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the companys selective oral DHODH inhibitor, in patients with relapsing-remitting multiple …
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *